Cleveland BioLabs, Inc. is a biopharmaceutical company investigating drugs to activate the immune system and address serious medical issues. Headquartered in Buffalo, New York, the firm has developed a platform of Toll-like immune receptor activators, with the primary candidate being Entolimod. In addition, they have other products, including CBLB612, Mobilan, and CBL0137, that have potential for treating various types of cancer.